Strain-Specific Anti-inflammatory Properties of Two <i>Akkermansia muciniphila</i> Strains on Chronic Colitis in Mice.
Zhai R, Xue X, Zhang L, Yang X, Zhao L, Zhang C. · 2019
Read Strain-Specific Anti-inflammatory Properties of Two <i>Akkermansia muciniphila</i> Strains on Chronic Colitis in Mice. by Zhai R, Xue X, Zhang L, Yang X, Zhao L, Zhang C. (2019) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc6624636.txt.
Introduction
Zhai and co-authors test two strains of a gut bacterium against chronic colitis in mice. Their research article appears in Frontiers in Cellular and Infection Microbiology. The bacterium, Akkermansia muciniphila, lives on mucin in the gut. Its type strain has eased obesity and diabetes in animal studies. Whether it helps bowel inflammation was unknown.
The team compared the type strain with a mouse isolate, strain 139. Both strains cut IL-8 output in cultured gut cells. In mice with DSS-driven colitis, both eased colon damage. They lowered TNF-α and IFN-γ levels in the colon. The type strain worked more strongly than strain 139. Only it shrank spleen weight and raised short-chain fatty acids. It also boosted regulatory T-cell formation. Both strains nudged the gut microbiota back toward normal.
Catalog record
| CREATOR | Zhai R, Xue X, Zhang L, Yang X, Zhao L, Zhang C. |
|---|---|
| YEAR | 2019 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 55 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Strain-Specific Anti-inflammatory Properties of Two Akkermansia muciniphila Strains on Chronic Colitis in Mice By Rui Zhai, Xinhe Xue, Liying Zhang, Xin Yang, Liping Zhao, Chenhong Zhang Published in: Frontiers in Cellular and Infection Microbiology DOI: 10.3389/fcimb.2019.00239 ABSTRACT Abstract Akkermansia muciniphila is potential probiotic in that its type strain ATCC BAA-835 has beneficial effects upon obesity and diabetes. However, whether A. muciniphila can improve inflammatory bowel diseases (IBD), which is a form of chronic intestinal dysbiosis, is unknown. Hence, we used an isolated murine A. muciniphila strain (designated 139) and A. muciniphila type strain ATCC, to investigate their anti-inflammatory properties in cell models and in Dextran Sulfate Sodium (DSS)-induced chronic colitis of mice. In vitro, the two A. muciniphila strains exerted similar anti-inflammatory properties as they both reduced IL-8 production by TNF-α-stimulated HT-29 cells. However, neither of the strains showed capacity to increase the differentiation of regulatory T (Treg)-cells from CD4+ T cell populations significantly. In vivo, both A. muciniphila strains exerted anti-inflammatory effects on chronic colitis as they improved clinical parameters including spleen weight, colon inflammation index, and colon histological score. They also down-regulated the expression of the pro-inflammatory cytokines including TNF-α and IFN-γ in the colon of mice. However, the anti-inflammatory effects of strain ATCC were stronger than strain 139 in that ATCC significantly reduced spleen weight, colon inflammation index, and fecal lipocalin-2 content in mice with chronic colitis, while strain 139 was not. Dysbiosis of the gut microbiota was observed in mice with chronic colitis. Both A. muciniphila strains facilitated the normalization of the gut microbiota. The specific capacity of strain ATCC to modulate the differentiation of Tregs as well as increase production of short chain fatty acids, demonstrated strain-specific characteristics for these two A. muciniphila strains. This study suggests the potential beneficial effect of A. muciniphila on IBD and the importance of the future study of the function of A. muciniphila at the strain-level. Keywords: Akkermansia muciniphila, strain-specificity, chronic colitis, DSS, Treg, gut microbiota INTRODUCTION Akkermansia muciniphila is a commensal bacterium of the intestinal tract, which uses mucin as its sole carbon and nitrogen source. Under anaerobic conditions, the bacterium produces acetate and propionate within mucin (Derrien et al., 2004). The type strain of A. muciniphila (ATCC BAA-835) was isolated from the feces of a healthy human. This bacterium is a promising candidate for next-generation probiotics in that it has beneficial effects in animal models of human disease including obesity, diabetes, and alcoholic liver disease (Cani and de Vos, 2017; Plovier et al., 2017; Grander et al., 2018). And its membrane protein, Amuc_1100, strengthens gut permeability and improves metabolic disorders of mice (Plovier et al., 2017). Despite obesity beneficial effects, controversies do exist regarding the effect of A. muciniphila on other diseases, including inflammatory bowel disease (IBD). IBD is a chronic inflammatory disorder related to the immune system and to the intestinal microbiota of the host (Maloy and Powrie, 2011). Many murine models of colitis induced by chemicals or by gene deficiency can be used to mimic the pathological or immunological features of IBD (Wirtz and Neurath, 2007). Several studies have found the abundance of Akkermansia to be decreased or unaltered in IBD patients (Png et al., 2010; Morgan et al., 2015; Lopez-Siles et al., 2018), while the abundance of Akkermansia demonstrated to be predominantly augmented in mice with colitis (Håkansson et al., 2015; Zhang et al., 2016). Extracellular vesicles of A. muciniphila ATCC BAA-835 have been shown to alleviate acute colitis in mice. However, the same strain was demonstrated to aggravate gut inflammation in gnotobiotic mice infected with Salmonella typhimurium (Ganesh et al., 2013; Kang et al., 2013). As such, the effect of Akkermansia on IBD remains unclear. Most investigations of A. muciniphila have assessed only one strain, ATCC BAA-835. Genomic analysis of 39 A. muciniphila strains from the gut of mammals revealed notable genomic diversity, which implies functional specificity (Guo et al., 2017). Strain-specific physiological properties in both beneficial species and pathogens have been revealed in many studies (Myers et al., 2006; Wu et al., 2017; Pan et al., 2018). Thus, investigation of the physiological properties of various A. muciniphila strains may be of value. Herein, the human-derived A. muciniphila strain ATCC BAA-835 and a novel murine A. muciniphila strain (designated as 139) were investigated for anti-inflammatory properties in vitro and in vivo. In vitro, both strains revealed anti-inflammatory characteristics but no immune-regulatory capacities. In the Dextran Sulfate Sodium (DSS)-induced chronic colitis murine model, ATCC BAA-835 significantly ameliorated intestinal inflammation, with increasing T regulatory cell (Treg) differentiation and short chain fatty acid (SCFA) production, while strain 139 did not show effect on the Treg differentiation and SCFAs production. However, both strains shifted the intestinal microbiota of mice. The work reported herein demonstrates the beneficial effects of A. muciniphila strains in chronic colitis as well as the existence of strain-specific anti-inflammatory properties of two A. muciniphila strains. MATERIALS AND METHODS Isolation of A. muciniphila Strain Fresh feces were collected from four specific pathogen free (SPF) 7-week-old C57/BL6 male mice (SLAC Inc., Shanghai, China) and suspended in anaerobic Ringer's solution (containing 0.05% L-cys). The suspensions were placed in an anaerobic work station (Don Whitley Scientific Ltd, Shipley, UK) within 10 min of harvest. Fecal matter was serially diluted 10-fold with Ringer's solution (containing 0.05% L-cys). The 10−3 dilution of suspension was placed onto mucin media plates (Derrien et al., 2004) and incubated under anaerobic condition (80% N2, 10% CO2, and 10% H2) at 37°C for 48 h until obvious colonies were observed. Isolated colonies (550) were purified by streaking three times on mucin media plates and identified as A. muciniphila by use of species-specific primers AM1 (5′-CAGCACGTGAAGGTGGGGAC-3′) and AM2 (5′-CCTTGCGGTTGGCTTCAGAT-3′) (Collado et al., 2007). Only three isolates were identified as A. muciniphila. Enterobacterial Repetitive Intergenic Consensus (ERIC) sequences of the genomes of the three isolates and A. muciniphila strain ATCC BAA-835 were amplified by polymerase chain reaction (PCR) using primers ERIC1 (5′-ATG TAAGCTCCTGGGGATTCAC-3′) and ERIC2 (5′-AAG TAAGTGACTGGGGTGAGCG-3′) (Vandamme et al., 1993). The three isolates shared the same ERIC-PCR profile and differed from strain ATCC BAA-835 (ATCC). One isolate (139) was randomly selected as representative and further identified by 16S rRNA gene sequencing, and identified as a new A. muciniphila strain. Culturing and Preparation of A. muciniphila Strains A. muciniphila strain ATCC and 139 were cultured anaerobically (80% N2, 10% CO2, and 10% H2) in synthetic media to stationary phase (Plovier et al., 2017). For preparation of bacterial culture supernatant (BCS), bacterial density was set to 0.2 (OD 600) in unfermented synthetic media, then centrifuged at 8000 × g for 20 min. The BCS was collected in another tube, sterilized using a 0.22 μm filter (Merck Millipore, MA, USA) and stored at −80°C. Bacteria for gavage were collected after centrifugation, washed once with 5 ml of anaerobic phosphate buffered saline (PBS, pH = 7.4), then resuspended in anaerobic PBS to a density of 2 × 1010 cfu/ml. The suspension was distributed into 4 ml centrifuge tubes (150 μl/tube) to which was added 150 μl PBS with 50% glycerin, mixed thoroughly and stored at −80°C. Before gavage, the stored bacterial cells were defrosted anaerobically and diluted to 1 × 109 cfu/ml by adding 2,700 μl of anaerobic PBS. Whole-Genome